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Patients were categorized according to baseline disease severity using MMSE score: 
mild (21-26), moderate (15-20), moderately severe/severe (< 15). Costs associated with 
patient and caregiver health care, patient social care and informal care were evalu-
ated using information from the Resource Use in Dementia instrument (RUD) and 
the data collection form. The primary objective was the estimation of total cost over 
the 18 months period. Total cost was estimated by applying country-specific unit 
costs. Supervision time and caregiver medical costs were excluded from the base 
case analysis. Imputation methods were used for missing cost data. Results: 419 
patients were enrolled (2010-2011) in 33 centers in France, 289 (69%) remained in the 
study at 18 months. Reasons for discontinuation were subject institutionalization 
(n= 65), death (n= 21) or other reason (n= 44). Total mean cumulative costs over the 
18-month period were estimated to be respectively 24140€ (21561-26863), 34287€ 
(30357-38939) and 44171€ (40050-48755) for mild, moderate and moderately severe/
severe patients (p< 0.001) with caregiver informal care cost accounting for approxi-
mately half of the total costs (52%, 53%, 51% respectively) (excluding supervision 
time). Mean overall monthly caregiver time increased over the 18-month period in 
each severity group, mainly driven by supervision time without significant differ-
ence between severity groups in terms of change from baseline. ConClusions: 
This longitudinal study showed that costs increase with AD severity. Informal care 
cost represents the largest part of total societal cost at each intermediate time point.
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objeCtives: In recent years, mental health problems have increased and people with 
mental disorders become more prevalent. This study aims to estimate the economic 
burden of people with mental disorders in Korea. Methods: The study evaluated the 
economic burden for people with mental disorders between 2008 and 2011 by sex and 
age. Direct and indirect costs were estimated using a prevalence based approach and 
calculated based on the four nationwide databases for people with disabilities(Korea 
National Health Insurance Corporation, the National Disability Registry of Ministry of 
Health and Welfare, the Korea National Statistical Offices’ records of cause of death, 
and National Survey on Persons with disabilities). The direct costs stem from both 
primary medical and non medical expenditures directly associated with mental dis-
orders. The indirect costs are estimated based on costs of lost productivity due to 
morbidity and premature mortality by applying a 3% of discount rate. Results: The 
results showed increases in both the prevalence of mental disorders by 1.2 times(from 
67,126 to 83,035) and total economic burden by 1.6 times(from $349.2 million to $562.6 
million) during 2008-2011. The proportions of direct costs over total economic burden 
were 89%($310.9 million) in 2008 and 91%($512.0 million) in 2011 and the proportions 
of indirect costs were 11%($38.4 million) and 9%($50.6 million) respectively. In addi-
tion, direct costs for male were 1.4 times higher than direct costs for female. The 
highest total socioeconomic costs($134.8 million~$201.4 million) were incurred by 
people aged 40-49 years. ConClusions: The prevalence and economic burden of 
mental disorders associated with direct costs increased for the years 2008 and 2011 
in Korea. These findings provide underlying evidence for mental health care improve-
ments and future studies are needed to investigate pharmacological and other social 
costs for mental disorders.
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objeCtives: Mental disorders constitute a major health problem with severe com-
plications and a significant impact on quality of life.This study is the first compre-
hensive study on the direct and indirect costs of mental disorders (schizophrenia, 
bipolar affective disorder, depressive episode, recurrent depressive disorder and 
reaction to severe stress, and adjustment disorders) and associated complications in 
Poland. Methods: In order to estimate the direct medical costs of mental disorders 
and their complications, including the costs of outpatient consultation, hospitaliza-
tion, rehabilitation, and drugs, data from the National Health Fund were used with 
related etiological fraction calculus. Indirect costs embraced costs of lost productiv-
ity due to absenteeism and inability to work (handicap) caused by these diseaeses, 
and costs of lost productivity due to the premature mortality. They were calcu-
lated upon Social Insurance Institution and Central Statistic Office datasets using 
human capital method. Results: Mental disorders is a cause of significant sickness 
absence and incapacity for work and therefore is associated with a growing pro-
ductivity decline in Poland. The share of indirect costs consitute almost 70% of total 
costs and indirect costs amounted to 760 mln EUR. The highest direct costs are asso-
ciated with treatment of mental disorders-related complications. ConClusions: 
The results of this study show that indirect costs can be higher than direct costs, and 
therefore cannot be ignored in health care decision-making processes. A major part 
of the total cost of analyzed mental disordes is indirect costs caused by productivity 
losses due to absenteeism and inability to work (65%). Most of these disorders can 
be successfully treated. The use of health care resources should be planned not only 
to cut direct costs of treatment but also to consider the social impact of the disease, 
through effective treatment to minimize indirect costs.
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objeCtives: Mental and behavioural disorders contributed 12.9% of the total bur-
den of disease in Australia, and pharmaceuticals are recommended as treatment 
objeCtives: Atypical antipsychotic-induced weight gain and metabolic side effects 
are key contributors to discontinuations and relapses among patients with schizo-
phrenia. Current treatment guidelines in Scotland recommend aripiprazole for 
adults with schizophrenia who are at risk of weight gain. Lurasidone is an atypical 
antipsychotic associated with a favourable metabolic side effect profile. The objec-
tive of this study was to conduct a cost-utility analysis to compare lurasidone with 
aripiprazole, and a budget impact analysis of introducing lurasidone treatment to 
patients with schizophrenia in the Scottish setting. Methods: A 10-year Markov 
model, incorporating a 6-week acute phase and a maintenance phase across three 
health states (stable on treatment, stable not on treatment, and relapse), was con-
structed. Baseline risks of discontinuation and relapse were derived from lurasi-
done clinical studies. Relative efficacy was taken from indirect comparisons. Costs 
included: drug therapy; relapse; outpatient; primary and residential care. Utility 
estimates were taken from literature. The budget impact analysis considered the 
difference between the acquisition cost of lurasidone per patient per year (PPPY) 
and the acquisition costs PPPY of medicines estimated to be displaced by lurasidone, 
and assumed that the uptake rate of lurasidone would be approximately 66% of that 
seen for aripiprazole in its first five years in the UK. Results: Lurasidone yielded 
a cost saving of £3,554 and a small quality-adjusted life-year (QALY) improve-
ment compared with aripiprazole. Deterministic sensitivity analysis indicated 
that results were sensitive to relapse rates. Probabilistic sensitivity analysis sug-
gested that lurasidone had the highest expected net benefit at all willingness-to-
pay thresholds. Lurasidone acquisition cost was £1,183 PPPY; the cost of displaced 
medicines was £1,182 PPPY. Lurasidone was therefore a budget neutral treatment 
option. ConClusions: Our analyses indicate that lurasidone is a clinically and 
cost-effective treatment option, which should have limited impact on prescribing 
budgets, when compared with aripiprazole.
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objeCtives: To calculate the variation in the drug cost involved in the treatment of 
depression during 2013-2015. Methods: Standard Treatment Guidelines (STG), 4th 
edition were perused to understand the management of depression. Current Index 
of Medical Specialities (CIMS) Oct. – Jan. 2015 issue were used to capture the price 
of drugs. Annual cost of drug treatment and its variation was studied. Results: 
According to STG, drugs needed for the treatment of depression includes Fluoxetine 
or Sertraline or Escitalopram or Venlafaxine or Mirtazapine or Imipramine or 
Amitryptylline. If we initiate the treatment with Fluoxetine 20mg OD, then the mini-
mum and maximum cost of treatment was found to be Rs.986-1789 annually. A total 
of 81% variation was observed in its minimum and maximum cost. Likewise, if the 
treatment is initiated with Amitryptylline 75mg OD, then we observed a variation of 
190% in its minimum and maximum cost of treatment. Similarly, 127% variation was 
noted for Escitalopram 10mg OD. ConClusions: A maximum of 3 fold variation was 
noted in the minimum and maximum cost of Amitryptylline. In Indian market a huge 
price variation exist, which is needed to regulate in order to maintain uniformity.
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objeCtives: The low reimbursed price of some “typical” antipsychotics could lead 
pharmaceutical companies to withdraw them from a given market, as a consequence 
of an unfavorable cost/revenue ratio. Aim of this work was to evaluate the clinical 
and economic implications of such an occurrence, i.e. of the “forced switch” of sta-
ble psychiatric patients. Methods: A Markov model was developed to identify all 
the possible scenarios related to the transition process from chlorpromazine and 
haloperidol to quetiapine (as possible examples). To replicate the “history” of a large 
number of hypothetical individual patients, a Monte Carlo simulation was performed. 
The outcomes of the switching and their impact were assessed using the estimated 
mean frequencies of the “lost to follow-up”, “died” and “stable condition” states, plus 
the estimated overall number of visits and ADRs. Transition probabilities and costs, 
from the perspective of NHS, were taken from published literature. A sensitivity 
analysis was also performed. Results: The “work” runs were performed with 500 
cohorts of 2000 subjects each, the simulations reached convergence after 26 cycles 
(corresponding to one year). Data analysis allowed to infer that 91% of the patients 
in treatment with chlorpromazine and haloperidol would be in stable conditions 
after one year from switching to quetiapine and that the incidence of ADRs would 
be 24 for 100 patients. During the first year of treatment each patient would return 
to the prescribing physician between 2-3 times. The “once-only” direct cost of the 
transition would be 1.5 - 2.5 million euros in Italy, followed by 5-7 million per year 
for new drug costs. ConClusions: This simulation confirms that, for both patients 
and NHS, “staying” with the present therapy would represent a better and more cost 
effective solution than switching, even if a higher reimbursed price were to be granted.
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disease in euroPe (geras) - 18-MonTH resulTs froM THe frencH coHorT
Rapp T1, Vellas B2, Andrieu S2, Chartier F3, Baraille L3, Belger M4
1University of Paris Descartes, Paris, France, 2Toulouse University Hospital, Toulouse, France, 3Eli 
and Lilly, Neuilly-sur-Seine Cedex, France, 4Eli Lilly and Company Ltd, Windlesham, UK
objeCtives: To describe 18-month health care resource use and costs associated 
with Alzheimer’s disease (AD) for patients and caregivers in France, stratified by AD 
severity at baseline. Methods: 18-month, prospective, multi-center, cohort study 
conducted in France, Germany and UK. Enrolled outpatients were > 55 years, diag-
nosed with probable AD (NINCDS-ADRDA) and had an informal caregiver available. 
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objeCtives: Ministry of Health, Labour and Welfare of Japan aims for the introduc-
tion of Health Technology Assessment in FY2016. Compared to foreign countries, a 
lack of resources for conducting the analysis has been pointed out in Japan. However, 
pharmaceutical and medical device industries are urged to seek practical approaches 
utilizing best available resources. The objective of this study was to review articles 
for cost-effectiveness analysis of major depression disease (MDD) and to evaluate 
analytical approaches that can be applied to Japanese environment. Methods: The 
literature search was conducted in MEDLINE and JDream III. Inclusion criteria are 
studies of 1) treatment for MDD, 2) cost-effectiveness analysis (CEA), 3) published in 
the past 10 years. Studies were assessed for the followings: country, model structure 
and simulation method, time horizon, perspective, source of key parameters, results, 
and key drivers determined from sensitivity analysis. Results: Twenty-three stud-
ies were reviewed in details. Markov (6 articles) and decision-tree (8 articles) models 
were adopted, and time horizon were relatively short, ranging from 8 weeks to 5 
years. Thirteen studies included costs of productivity loss. Costs were based on lit-
erature or expert opinion in 21 studies. Utility scores were referred to other studies 
(17 articles). Parameters which became key drivers for these analyses varied among 
studies. ConClusions: Data collection methods adopted in prior studies were con-
sidered applicable to CEA for UC treatment in Japan. Cost data can be obtained not 
only from questionnaire survey to doctors but commercial database. Because evidence 
on utility scores of Japanese population is still limited, further studies will be needed, 
especially on MDD patients in depression, remission, and relapse phase of treatment.
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objeCtives: Patients with chronic schizophrenia are difficult to manage and costly 
to the health system. The European Medicines Agency has approved paliperidone 
palmitate (PP-LAI; Xeplion®), an atypical antipsychotic depot which is adminis-
tered monthly. However, its pharmacoeconomic profile in Portugal is unknown. 
Therefore, we conducted a cost-effectiveness analysis from the analytic viewpoint 
of the Portuguese National Health Service. Methods: PP-LAI was compared with 
long acting injectable forms of risperidone (RIS-LAI) and haloperidol (HAL-LAI) as 
well as oral drugs (oral-OLZ) using a 1-year decision tree previously used in Europe 
and adapted to Portugal with guidance from clinical experts. We obtained clinical 
information and costs from literature sources and published lists. Clinical out-
comes included relapses (both requiring and not requiring hospitalization), days 
with relapse, and quality-adjusted life-years (QALYs). Costs were expressed in 
2015 euros. Economic outcomes included a cost-utility (incremental cost/QALY) 
and cost-effectiveness analyses (incremental cost/relapse as well as hospitalization 
avoided). Results: PP-LAI had the lowest rates for all negative events. Respective 
outcomes for PP-LAI, RIS-LAI, HAL-LAI and oral-OLZ included relapse days (37.4, 51.2, 
79.5, 78.0), Emergency Room visits (0.122, 0.168, 0.250, 0.242), hospitalizations (0.288, 
0.394, 0.623, 0.615) and QALYs (0.8227, 0.7985, 0.7585, 0.7609). Expected costs were 
lowest for oral-OLZ (4447€ ), followed by 4474€ for HAL-LAI, 5326€ for PP-LAI, and 
6223€ for RIS-LAI. HAL-LAI and RIS-LAI were both dominated and eliminated from 
further consideration. PP-LAI had an ICER of 14,247€ /QALY gained over oral-OLZ, 
which was considerably below the NICE threshold (≈27,600€ ). In cost-effectiveness 
analyses, PP-LAI had ICERs of 1902€ /relapse avoided and 2626€ /hospitalization 
avoided. Model drivers were hospitalization for HAL-LAI (74%) and oral-OLZ (59%); 
for PP-LAI 49% was due to drug and 39% hospitalization and for RIS-LAI it was 44% 
drug and 44% hospitalization. ConClusions: PP-LAI is cost-effective in Portugal 
when compared with the customary treatments.
PMH26
PHarMacoeconoMic eValuaTion of ariPiPrazole once-MonTHly 
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objeCtives: As a chronic illness, schizophrenia consumes a vast amount of health-
care resources and is therefore associated with both high direct and indirect health-
care costs. Pervasive suboptimal quality of life coupled with a high economic burden 
renders policy and healthcare decision makers seeking cost-effective treatments. This 
study aimed at evaluating the cost-effectiveness of aripiprazole once-monthly 400mg 
(AOM) versus paliperidone palmitate 50-150mg (PP) in the maintenance treatment 
of schizophrenia based on the QUALIFY study (NCT01795547). Methods: QUALIFY 
was a 28-week, randomised, open-label, rater-blinded study comparing AOM with PP 
in the maintenance treatment of schizophrenia. Two key outcomes demonstrated 
improvements for AOM vs. PP: Heinrichs-Carpenter Quality of Life Scale (QLS) and 
Clinical Global Impression – Severity (CGI-S). To assess cost-effectiveness, minimal 
clinically important differences (MCIDs) were sought from the literature in the respec-
tive assessment scales. Treatment response was defined as a change from baseline to 
study termination of at least 6 points and 1 point on QLS total score and CGI-S score, 
respectively. Mean treatment specific costs (incl. drug acquisition) were estimated 
using QUALIFY healthcare resource utilisation data. The analysis was conducted from 
a UK perspective considering direct costs only. Results: In the deterministic analysis 
mean total costs per-patient were £2,093 and £2,954 for AOM and PP, respectively 
for people with moderate to severe conditions. The aim of this research was to 
estimate the costs of pharmaceuticals to the Australian public health sector and 
the most frequently prescribed drugs for the three most prevalent mental illnesses: 
depression, anxiety-related, and substance use disorders. Methods: The National 
Survey of Mental Health and Wellbeing(NSMHWB) has been conducted every 10 
years since 1997, collecting epidemiology and economic impact to Australian soci-
ety. Respondents diagnosed within the preceding 12 months with depression (D), 
anxiety-related disorders (ANX), and substance use disorders (SUB) by ICD-10 in 
NSMHWB 2007 were included in the analysis. The NSMHWB 2007 reported the 
duration and the name of up to five drugs used during the past 12-month period. 
In order to adjust for inflation, 2013-14 reference year was adopted for the unit 
cost of each drug obtained from Pharmaceutical Benefit Scheme (PBS). Results:: 
Around 23% of respondents used medications for a total cost to the society of AUD 
101 million (SE 11.9). Citalopram was the most frequently prescribed drug (17.11%), 
followed by venlafaxine (15.65%), sertraline (14.43%), and temazepam (10.51%). 
Respondents reported with D+ANX+SUB had the highest percentage in use of 
medications (63.85%), followed by D+ANX (44.26%), and D (34.74%). ANX accounted 
for 50% of total medication costs followed by D+ANX at 23.6%. ConClusions:: 
The high prevalence of ANX contributed to the large proportion of medication costs 
for this condition.
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objeCtives: Aripiprazole once-monthly (AOM) is a long-acting injectable formula-
tion of aripiprazole, and is approved in Europe for the maintenance treatment of 
schizophrenia after stabilization with oral aripiprazole. The objective of this research 
was to evaluate the cost-effectiveness of AOM versus paliperidone palmitate (PP) in 
the maintenance treatment of schizophrenia in Spain. Methods: This pharmaco-
economic evaluation was conducted alongside a 28-week, randomized, open-label, 
rater-blinded study comparing AOM 400mg and PP (50-150mg) in stabilized adults 
with schizophrenia. Effectiveness outcomes of the cost-effectiveness analyses (CEA) 
included the changes in Heinrichs-Carpenter Quality of Life Scale (QLS-primary CEA) 
and Clinical Global Impression-Severity (CGI-S) score at week 28. Visits with health-
care providers, out- and in-patient services were collected using a health economic 
assessment questionnaire (HEA). Healthcare services unit costs from the Basque 
Country were used (2014 costs). All patients with at least one valid post-baseline 
HEA were eligible for analysis. Bootstrapped confidence intervals were generated 
from 10,000 simulations, as well as cost-effectiveness acceptability curves. Results: 
Over the total 28-week period, AOM was associated with significantly reduced total 
healthcare costs compared to PP (mean per-patient cost: € 1,935 vs. € 2,475, respec-
tively; p< 0.001). This cost reduction was primarily due to significant reduction in drug 
acquisition costs (€ 1,237 vs. € 1,889; p< 0.001). The other cost aggregates (healthcare 
provider costs, out- and in-patient costs) were not statistically different between drugs 
(p= 0.528, p= 0.102 and p= 0.194, respectively). In the primary CEA, AOM dominated 
PP (being more effective on the QLS scale and less costly). This result was confirmed 
when using CGI-S as effectiveness measure. The cost-effectiveness acceptability 
curves indicated that AOM was the treatment of choice whatever willingness-to-pay 
threshold used. ConClusions: Aripiprazole once-monthly was associated with 
statistically significantly reduced healthcare costs and greater effectiveness com-
pared to paliperidone palmitate in all scenarios, showing its economic value in the 
management of maintenance schizophrenia in Spain.
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cosT-effecTiVeness analysis of THe inforMaTion TecHnology aided 
relaPs PreVenTion PrograMMe in scHizoPHrenia (iTarePs) in THe 
czecH rePuBlic
Mlcoch T, Kruntoradova K, Mandelikova M, Dolezal T
Institute of Health and Technology Assessment, iHETA, Prague, Czech Republic
objeCtives: Information technology aided relapse prevention programme in 
schizophrenia (ITAREPS) is a unique mobile phone-based telemedicine solution 
for weekly remote patient monitoring and disease management of psychotic 
disorders in general, particularly of schizophrenia. RCTs evidence suggests that 
ITAREPS is highly effective in decreasing hospitalization schizophrenia relapses. 
Based on these RCTs, we performed a cost-utility analysis of ITAREPS compared to 
the treatment of schizophrenia without ITAREPS in the Czech Republic. Methods: 
We developed a 20-year Markov cohort model with yearly cycle length and four 
health states, i.e. without relapse, with non-hospitalization relapse, with hospi-
talization relapse and death. Transition probabilities and resource use were derived 
from the Czech RCT and utilities were derived from published literature. Costs 
were calculated from healthcare payer’s perspective. Costs and outcomes were 
discounted by 3%. Probabilistic sensitivity analysis (PSA) with 3000 iterations was 
performed. Results: Over a 20-year time horizon, ITAREPS compared to non-
ITAREPS brings additional 0.21 QALY (12.33 vs. 12.12). The incremental total costs 
were -€ 5,554 (€ 55,435 vs. € 60,989) for ITAREPS. The insignificantly higher costs of 
ITAREPS service itself (€ 155 in the first and € 120 in subsequent years) are there-
fore vastly offset by savings of hospitalization relapse costs (€ 1,243 vs. € 11,748); 
ITAREPS on average prevents 5 hospitalization relapses in 20-year time horizon 
(0.73 vs. 5.77 hospitalizations) per patient. The results of the PSA show that ITAREPS 
is cost-effective in 93% iterations under the WTP threshold equal to € 0. An exten-
sive scenario analysis confirmed the base-case results, ITAREPS was dominant in 
all scenarios. ConClusions: ITAREPS is a highly cost-effective intervention in 
patients with schizophrenia and it is even a dominant intervention in comparison 
with non-ITAREPS since it is more effective in terms of QALY gained and cheaper 
at the same time. There is even 93% probability of ITAREPS being cost-effective at 
the WTP threshold equal to € 0.
